Abstract. Prostate cancer (PCa) remains a major cause of mortality among males in western countries, with little change in mortality rates observed over the past 25 years. Despite recent advances in therapy, treatment options for metastatic castration-resistant disease remain limited. In terms of chemotherapy, only the combination of docetaxel and prednisone has been shown to improve survival in these patients, but duration of response to therapy is short. There is a continuing unmet need for new systemic interventions that act either alone or synergistically with chemotherapy in patients with progressive PCa. Angiogenesis plays a critical role in tumor growth and metastasis in PCa. Several strategies have been used to target angiogenesis; however, it is becoming increasingly apparent that current anti-angiogenic therapies frequently achieve only modest effects in clinical settings. The RhoA/Rho kinase (ROCK) pathway plays a crucial role in the process of angiogenesis in PCa, and studies have demonstrated that ROCK inhibitors decrease VEGF-induced angiogenesis and tumor cell growth. However, further research is required to fully elucidate the molecular mechanisms involved in this pathway, and the potential value of modulating these mechanisms in the treatment of PCa. This study reviews the current understanding of the role of the RhoA/ROCK pathway in the process of angiogenesis in PCa, and the potential of this pathway as a therapeutic target in the future.

Contents
1. Introduction
2. Role of angiogenesis in prostate cancer
3. Role of the RhoA/Rho kinase pathway in angiogenesis
4. RhoA/Rho kinase pathway and angiogenesis in prostate cancer
5. Implications for therapy
6. Conclusion

1. Introduction

Prostate cancer (PCa) is the most common malignancy and the second leading cause of cancer-related mortality in males in western countries. Advanced and metastatic stages of the disease were present in 35% of 1,589 patients with PCa diagnosed by autopsy (1). Among those patients with localized cancer who are able to receive radical prostatectomy (RP), ~35% will develop a recurrence (metastatic disease) within the 10 years following surgery (2,3). For those who present at initial diagnosis or progress with advanced or metastatic disease, androgen deprivation therapy (ADT) can be effective. However, the median duration of response to ADT is limited to between 8 months and 3 years (4), and these patients will eventually become castration resistant. Another effective treatment for castration-resistant PCa is chemotherapy, although the median duration of response is only 10.3 months (5). Therefore, there is a clear and urgent need to develop additional systemic interventions for patients with progressive PCa.

2. Role of angiogenesis in prostate cancer

Angiogenic switch. Angiogenesis plays a critical role in PCa progression and metastasis. Without neovascularization, tumor growth will stop at a diameter of 2-3 mm (6). Once tumor cells are able to make their own new blood vessels, they can further expand and metastasize in a process termed the ‘angiogenic switch’ (7). The angiogenic switch in tumors is due to a shift in the balance towards neovascularization, when pro-angiogenic factors outweigh anti-angiogenic factors (8). Cancer cells and other cells in tumor tissue, such as macrophages and fibroblasts, can secrete pro-angiogenic factors, including vascular
endothelial growth factor (VEGF), basic fibroblast growth factor and interleukin 8, which promote the formation of new blood vessels, causing an increase in microvessel density (MVD) in cancer tissue.

MVD. MVD has been found to be greater in PCa than in benign prostatic hyperplasia (BPH) and normal tissue (9,10). It has been reported that MVD increases with increasing Gleason score in PCa, particularly in the poorly differentiated type (11). The MVD was also significantly correlated with cancer-specific survival in 221 patients with PCa followed for a median of 15 years (12). In other studies, mean MVD was found to correlate with increasing Gleason score and disease progression (from extraprostatic extension to metastasis) in PCa (13,14). Weidner et al showed that MVD was significantly higher in PCa samples from patients with metastatic disease, compared with those from patients without metastatic disease (11). Results from another study indicated that PCa angiogenesis correlated with progression after RP in patients with a Gleason score >7 (15). These data highlight the important role of angiogenesis in the progression and metastasis of PCa. MVD counts have also been shown to potentially predict tumor progression from high-grade intraepithelial neoplasia to PCa, as well as outcome in patients undergoing RP (16).

VEGF and angiogenesis in PCa. As tumors undergo an angiogenic switch, many pro-angiogenic growth factors are secreted. Among these, VEGF is the most significant and also the most prominent regulator of physiological angiogenesis. Cells in tumor tissue, including cancer cells, fibroblasts and macrophages, secrete VEGF to stimulate new vessel formation in response to hypoxia (17,18).

Clinical studies comparing PCa with BPH revealed that VEGF expression was correlated with increased levels of angiogenesis, and that this was at least partly mediated by VEGF (10). In PCa, serum levels of the humoral ligand, VEGF, have been found to be significantly higher in patients with metastatic disease, compared with those patients with localized disease or healthy controls (19). Plasma VEGF levels have also been found to be an independent prognostic factor in males with metastatic PCa (20). Peyromaure et al compared 17 patients who developed bone metastases after RP with 23 patients who remained disease free and found that the expression of VEGF was significantly higher in the former group (21). Levels of VEGF in serum, plasma or urine are correlated with patient outcome in both localized as well as disseminated PCa (22). In a study of 50 patients with locally advanced disease treated with radical radiotherapy, Green et al reported a correlation between higher VEGF expression and worse disease-specific survival (23). In addition, levels of the VEGFR cognate receptor were found to be associated with a poorer grade of tumor differentiation and prognosis in PCa (24). Given these findings, angiogenesis inhibition has been targeted as a strategy to treat PCa. However, it has become increasingly apparent that current anti-angiogenic therapy targeting VEGF elicits only modest effects in clinical settings.

3. Role of the RhoA/Rho kinase pathway in angiogenesis

RhoA and its activation. RhoA is a small guanosine triphosphate hydrolase (GTPase) belonging to the Ras homology (Rho) family. The Rho family of GTPases comprise at least 23 members (25,26), which serve as key regulators of extracellular stimulus-mediated signaling networks involved in a diversity of cellular processes including motility, mitosis, proliferation and apoptosis (27). RhoA promotes actin stress fiber formation and focal adhesion assembly.

Rho GT Pases function as molecular switches, cycling between an active GTP-bound conformation and an inactive guanosine diphosphate (GDP)-bound conformation (28,29). When binding with GTP, they interact with downstream effectors to propagate signal transduction (30). Intrinsic phosphatase activity hydrolyzes GTP to GDP, deactivating RhoA function, and this process is accelerated by interaction with GTPase-activating proteins. Conversely, interaction with guanine-nucleotide exchange factors facilitates the exchange of GDP to GTP, which restores the activation of RhoA. The relative affinity difference of the effector molecules between the GTP- and GDP-bound states of the Rho GTPase can be as much as 100-fold, resulting in a highly-specific interaction only with the GTP-bound activated state (Fig. 1). In addition, Rho proteins are also regulated by guanine nucleotide dissociation inhibitors (GDIs), which can inhibit both the exchange of GDP to GTP and the hydrolysis of bound GTP. In the majority of cases, Rho proteins are post-translationally modified at their C-termini by prenylation of a conserved cysteine, and this facilitates their attachment to cell membranes.

ROCK and its function. Rho kinase (ROCK) is a serine/threonine kinase with a molecular mass of ~160 kDa, which has been shown to be the principle downstream target of RhoA. There are two ROCK isoforms: ROCK1 (ROCKβ or p160 ROCK) and ROCK2 (ROCKα or Rho kinase). ROCK1 and ROCK2 show an overall homology of 65% in their amino acid sequence and 92% in their kinase domains. Both ROCK1 and ROCK2 are expressed in vascular endothelial cells (ECs) (31,32).

When bound and activated by RhoA, ROCK translocates from the cytoplasm to the cell membrane, where it increases phosphorylation of the myosin light chain (MLC) of myosin II. This is achieved either by direct phosphorylation, or by phosphorylation of the regulatory myosin-binding subunit of myosin phosphatase (also known as the phosphatase-targeting subunit), which inhibits the phosphatase activity of this molecule (33). This, in turn, enhances actin binding and the actin-induced adenosine triphosphatase activity of myosin, facilitating the interaction of myosin with F-actin, and ultimately cell contractility. ROCK proteins can also phosphorylate coflin indirectly via LIM kinase, and this facilitates the organization of F-actin into stress fibers and re-arrangement of the actin cytoskeleton (30).

RhoA/ROCK pathway and cell motility. In eukaryotes, organization and reorganization of the cytoskeleton underpins cellular morphology and motility. The actin cytoskeleton is composed of actin filaments and numerous specialized actin-binding proteins. Actin filaments are created by the simple polymerization of actin monomers, regulated dynamically by numerous upstream signaling pathways, notably Rho GTPases (30). A coordinated regulation of the actin network is essential to produce directed cell movement.
Angiogenesis is a five-step process involving a complex series of events. Firstly, an increase in the permeability of the basement membrane allows a new capillary to sprout. Next, ECs activated by angiogenic factors migrate through the basement membrane into the extracellular matrix, towards the angiogenic stimulus. The leading front of migrating cells is driven by enhanced proliferation of ECs, which constricts and cleaves the cell, forming two daughter cells. Inhibition of RhoA dominant-negative mutant vector or by a RhoA inhibitor C3 (42). Zhao et al showed that increased expression of RhoA in human umbilical vein ECs significantly enhanced cytoskeletal reorganization of transfected cells, cell migration and angiogenic capacity, which suggests that RhoA plays a key part in these processes in vitro (43).

Migration. The formation of stress fibers and cellular contraction is essential for EC migration, and these processes are mediated by Rho GTPases (41). van Nieuw Amerongen et al demonstrated in vitro that VEGF induces the activation of RhoA and this increase in RhoA activity is necessary for VEGF-induced reorganization of the F-actin cytoskeleton. This process can be inhibited by transfection of ECs with a RhoA dominant-negative mutant vector or by a RhoA inhibitor C3 (42). VEGF, vascular endothelial growth factor.

Pro-angiogenic factors can activate the RhoA/ROCK pathway in angiogenesis. Pro-angiogenic factors can activate the RhoA/ROCK pathway subsequently activate the downstream molecules that take part in the multisteps of angiogenesis. Firstly, MYPT-1 can be activated by ROCK and cause myosin light chain phosphorylation followed by actin-mediated EC contraction, which leads to an increase in the permeability of the basement membrane allowing a new capillary to sprout. Other molecules involved in cytoskeletal organization, such as LIMK and cofilin, are activated and cause ECs to migrate into the extracellular matrix towards the angiogenic stimulus. The leading front of migrating cells is driven by enhanced proliferation of ECs, in which ERK1/2 and cyclin may play a role when activated by ROCK. This is followed by re-organization of ECs to form tubules with a central lumen, which finally reorganize to result in new capillary stabilization. ROCK, Rho kinase; MYPT-1, myosin phosphatase target subunit 1; ECs, endothelial cells; ERK1/2, extracellular signal-regulated kinase 1/2.

Permeability. The endothelium is a semi-permeable barrier that lines the vasculature, comprising ECs that are connected to each other by interendothelial junctions, consisting of protein complexes organized as tight junctions and adherent junctions. The latter are in the majority (38), and are composed of vascular endothelial (VE) cadherin that associates homotypically with VE-cadherin on adjacent cells. VE-cadherin binds to the actin cytoskeleton. Actin-mediated EC contraction occurs as a result of MLC phosphorylation, and this can cause dysfunction of the endothelial barrier by inducing the formation of small gaps between neighboring cells (39). RhoA, through its downstream effector ROCK, plays a role in endothelial barrier dysfunction by potentiating MLC phosphorylation via inhibition of MLC phosphatase activity. Studies have also confirmed that RhoA contributes to VEGF-induced hyperpermeability in the endothelium (40).
cell adhesion and the induction of p53 and other pro-apoptotic proteins, or via ceramide upregulation leading to caspase cleavage and subsequent activation (46,47). Studies have shown that the ROCK inhibitors, fasudil and Y-27632, not only inhibit VEGF-induced cell proliferation, but also reverse the protective effect of VEGF on apoptosis, which results in a decrease in viability of VEGF-stimulated ECs (48,49). Data obtained with these inhibitors have revealed the important role of the RhoA/ROCK pathway in EC proliferation and cell viability.

*Morphogenesis.* Cultured ECs can undergo marked changes in shape and tube formation that closely imitate pre-capillary cord formation *in vivo* (50). *In vitro* angiogenesis assays found that the mean tube length of the capillary-like tubular structures formed by ECs was reduced by transfection of a RhoA dominant-negative mutant vector, the RhoA inhibitor C3, or the ROCK inhibitor Y-27632 (42). In another study, Zhao et al demonstrated that overexpression of RhoA increased the tube length in transfected ECs (43).

4. RhoA/ROCK pathway and angiogenesis in prostate cancer

As discussed previously, the RhoA/ROCK pathway participates in the process of angiogenesis in numerous types of cancer, including PCa. Tumor blood vessels always exhibit abnormal structure and function. A study investigating the ECs of mice carrying the transgenic adenocarcinoma of the mouse prostate transgene revealed that the aberrant mechanosensing of extracellular matrix cues and resulting abnormal responses in these cells correlated with a constitutively high level of baseline activity of Rho GTPase and its downstream effector, ROCK (51). These findings highlighted the important role of the RhoA/ROCK pathway in the angiogenesis of PCa. A number of other studies have also demonstrated that RhoA/ROCK pathway inhibitors decrease angiogenesis and cell growth in PCa (52-54).

In an *in vitro* study, Y-27632 inhibited metastatic growth of highly invasive PC3 cells in immunocompromised mice (52). Another ROCK inhibitor, Wf-536, greatly enhanced the *in vitro* inhibition of EC migration, vacuolation, lumen and cord formation, and VEGF- and hepatocyte growth factor-stimulated endothelial sprout formation, when combined with the matrix metalloproteinase inhibitor, marimastat (53). Early treatment with a combination of Wf-536 plus marimastat, with or without pachatexal, of immunocompromised mice bearing xenotransplants of PC3 cells was associated with significant inhibition of tumor growth and increased tumor necrosis (53). Certain potential anti-angiogenic medications, such as anacardic acid, have been found to inhibit human prostate tumor xenograft angiogenesis by targeting the Rho GTPase signaling pathway (54).

5. Implications for therapy

VEGF antibody bevacizumab has been approved for numerous cancer therapies, such as for colon, lung and kidney cancer. One of its main side effects is hypertension, while ROCK inhibitors have vasodilatation effects. For example, fasudil has shown favorable effects in patients with angina (55) and pulmonary hypertension (56) in clinical trials and has been approved for cerebral vasospasm by the inhibition of vessel contraction. Their effects on anti-angiogenesis have also gradually been discovered, as we have reviewed above. It may be feasible to combine the ROCK inhibitor with VEGF antibody in order to enforce their anti-angiogenesis effects while reducing the side effects.

6. Conclusion

Inhibition of angiogenesis has been targeted as a strategy to treat PCa. Until now, the main focus has been on the VEGF pathway. However, it has become increasingly apparent that current anti-angiogenic therapy elicits only modest effects in clinical settings. The RhoA/ROCK pathway plays a crucial role in cancer angiogenesis and should also be a potential target for anti-angiogenic therapy. Additional studies are required to elucidate the molecular mechanisms of the RhoA/ROCK pathway in PCa angiogenesis, and the potential value of modulating these mechanisms for the treatment of PCa.

Acknowledgements

This study was supported by grant from the Program of International Science and Technology Cooperation (grant no. 2012DFG31440) of the Ministry of Science and Technology, China.

References

1. Bubendorf L, Schöpfer A, Wagner U, et al: Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 31: 578-583, 2000.
2. Roehl KA, Han M, Ramos CG, Antenor JA and Catalona WJ: Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol 172: 910-914, 2004.
3. Hull GW, Rabbani F, Abbas F, Wheeler TM, Kattan MW and Scardino PT: Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol 167: 528-534, 2002.
4. Daneshgari F and Crawford ED: Endocrine therapy of advanced carcinoma of the prostate. Cancer 71: 1089-1097, 1993.
5. Eymard JC, Oudard S, Gravis G, et al: Docetaxel reintroduction in patients with metastatic castration-resistant doceatxel-sensitive prostate cancer: a retrospective multicentre study. BJU Int 106: 974-978, 2010.
6. Folkman J, Cole P and Zimmerman S: Tumor behavior in isolated perfused organs: in vitro growth and metastases of biopsy material in rabbit thyroid and canine intestinal segment. Ann Surg 164: 491-502, 1966.
7. Banerjee S, Dowsett M, Ashworth A and Martin LA: Mechanisms of disease: angiogenesis and the management of breast cancer. Nat Clin Pract Oncol 4: 536-550, 2007.
8. Bergers G and Benjamin LE: Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3: 401-410, 2003.
9. Bigler SA, Deering RE and Brawer MK: Comparison of microscopic vascularity in benign and malignant prostate tissue. Hum Pathol 24: 220-226, 1993.
10. Stefanou D, Batistatou A, Kamina S, Arkoumani E, Papachristou DJ and Avalidis NJ: Expression of vascular endothelial growth factor (VEGF) and association with microvessel density in benign prostate hyperplasia and prostate cancer. In Vivo 18: 155-160, 2004.
11. Weidner N, Carroll PR, Flax J, Blumenfeld W and Folkman J: Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 143: 401-409, 1993.
12. Borre M, Offerens BV, Nerström B and Overgaard J: Microvessel density predicts survival in prostate cancer patients subjected to watchful waiting. Br J Cancer 76: 940-944, 1997.
13. Brawer MK, Deering RE, Brown M, Preston SD and Bigler SA: Predictors of pathologic stage in prostate carcinoma. The role of neovascularity. Cancer 73: 678-687, 1994.
RhoA: The effect of RhoA on human endothelial function and cell survival. Functions of vascular endothelial growth factor (VEGF). J Cell Mol Med 9: 777-794, 2005.

Dvorak HF, Detmar M, Claffey KP, Nagy JA, de Water L and Senger DR: Vascular permeability factor/vascular endothelial growth factor: an important mediator of angiogenesis in malignancy and inflammation. Int Arch Allergy Immunol 107: 233-255, 1995.

Duque JL, Loughlin KR, Adam RM, Kantoff PW, Zarakowski D and Freeman MR: Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. Urology 54: 523-527, 1999.

George DJ, Halabi S, Shepard TF, et al: Cancer and Leukemia Group B 9480: Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin Cancer Res 7: 1932-1936, 2001.

Peyromaure M, Camparo P, Badoual C, Desczaeaud A and Dinh-Xuan AT: The expression of vascular endothelial growth factor is associated with the risk of cancer progression after radical prostatectomy. BJU Int 99: 1150-1153, 2007.

Bok RA, Halabi S, Fei DT, et al: Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study. Cancer research 61: 2533-2536, 2001.

Green MM, Hiley CT, Shanks JH, et al: Expression of vascular endothelial growth factor (VEGF) in locally invasive prostate cancer is prognostic for radiotherapy outcome. Int J Radiat Oncol Biol Phys 67: 84-90, 2007.

Huss WJ, Hanrahan CF, Barrios RJ, Simons JW and Greenberg NM: Angiogenesis and prostate cancer: identification of a molecular progression switch. Cancer Res 61: 2726-2743, 2001.

Wennerberg K, Rossman KL and Der CJ: The Ras superfamily at a glance. J Cell Sci 118: 843-846, 2005.

Bustelo XR, Sauzeau V and Berenjeno IM: GTPase signaling pathway. J Pharmacol Exp Ther 339: 403-411, 2011.

Somlyo AV, Phelps C, Dipierro C, Somlyo AP: Rho-kinase inhibitor retards migration and invasion of human prostate cancer cells. J Cell Biol 147: 831-844, 1999.

Petrache I, Crow MT, Neuss M and Garcia JG: Central involvement of Rho family GTPases in TNF-alpha-mediated bovine pulmonary endothelial cell apoptosis. Biochem Biophys Res Comm 306: 244-249, 2003.

Yin L, Morishige K, Takahashi T, et al: Fasudil inhibits vascular endothelial growth factor-induced angiogenesis in vitro and in vivo. Mol Cancer Ther 6: 1517-1525, 2007.

Bryan BA, Dennstedt E, Mitchell DC, et al: RhoA/ROCK signaling is essential for multiple aspects of VEGF-mediated angiogenesis. FASEB J 24: 3186-3195, 2010.

Montesano R, Orci L and Vassalli P: In vitro rapid organization of endothelial cells into capillary-like networks is promoted by collagen matrices. J Cell Biol 97: 1648-1652, 1983.

Warsame M, Moretti A, Kyprianou N: Targeting vasculature in urologic tumors: mechanistic and therapeutic significance. J Cell Biochem 103: 691-708, 2008.

Mebius R and Malik AR: Signaling mechanisms regulating endothelial permeability. Physiol Rev 86: 279-367, 2006.

Dudek SM and Garcia JG: Cytoskeletal regulation of pulmonary vascular permeability. J Appl Physiol (1985) 91: 1487-1500, 2001.

Sun H, Breslin JW, Zhu J, Yuan SY and Wu MH: Rho and ROCK signaling in VEGF-induced microvascular endothelial hyperpermeability. Microcirculation 13: 237-247, 2006.

Kioseos WB, Daniels RH, Otey C, Bokoch GM and Schwartz MA: A role for p21-activated kinase in endothelial cell migration. J Cell Biol 147: 831-844, 1999.

van Nieuw Amerongen GP, Koolwijk P, Versteijl A and van Hinsberg VV: Involvement of RhoA/Rho kinase signaling in VEGF-induced endothelial cell migration and angiogenesis in vitro. Atheroscler Thromb Vasc Biol 23: 211-217, 2002.

Zhao L, Xu G, Zhou J, et al: The effect of RhoA on human umbilical vein endothelial cell migration and angiogenesis in vitro. Oncol Rep 15: 1147-1152, 2006.

Van Aelst L and D’Souza-Schorey C: Rho GTAPases and signaling networks. Genes Dev 11: 2295-2322, 1997.

Glotzer M: Animal cell cytokinesis. Annu Rev Cell Dev Biol 13: 565-592, 1997.

Bono AV, Celato N, Cova V, Salvadore M, Chinetti S and Bresolin ML: Increased arginase activity and NO production in the RhoA pathway: implications for atherosclerotic endothelial dysfunction. Heart 91: 391-392, 2005.

Byrne AM, Boucher-Hayes DJ and Harmey JH: Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF). J Cell Mol Med 9: 777-794, 2005.

Ming XF, Barandier C, Viswambharan H, Somlyo AV, Barrios RJ, Simons JW and Greenberg NM: Angiogenesis and prostate cancer: identification of a molecular progression switch. Cancer Res 61: 2726-2743, 2001.

Angiogenesis and prostate cancer is prognostic for radiotherapy outcome. Int J Radiat Oncol Biol Phys 67: 84-90, 2007.

Moore NT, Senger DR: Vascular permeability factor: an important mediator of angiogenesis in vitro. J Cell Biol 147: 831-844, 1999.

van Nieuw Amerongen GP, Koolwijk P, Versteijl A and van Hinsberg VV: Involvement of RhoA/Rho kinase signaling in VEGF-induced endothelial cell migration and angiogenesis in vitro. Atheroscler Thromb Vasc Biol 23: 211-217, 2002.

Zhao L, Xu G, Zhou J, et al: The effect of RhoA on human umbilical vein endothelial cell migration and angiogenesis in vitro. Oncol Rep 15: 1147-1152, 2006.

Van Aelst L and D’Souza-Schorey C: Rho GTAPases and signaling networks. Genes Dev 11: 2295-2322, 1997.

Glotzer M: Animal cell cytokinesis. Annu Rev Cell Dev Biol 13: 565-592, 1997.

Bono AV, Celato N, Cova V, Salvadore M, Chinetti S and Bresolin ML: Increased arginase activity and NO production in the RhoA pathway: implications for atherosclerotic endothelial dysfunction. Heart 91: 391-392, 2005.

Byrne AM, Boucher-Hayes DJ and Harmey JH: Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF). J Cell Mol Med 9: 777-794, 2005.

Ming XF, Barandier C, Viswambharan H, Somlyo AV, Barrios RJ, Simons JW and Greenberg NM: Angiogenesis and prostate cancer: identification of a molecular progression switch. Cancer Res 61: 2726-2743, 2001.

Angiogenesis and prostate cancer is prognostic for radiotherapy outcome. Int J Radiat Oncol Biol Phys 67: 84-90, 2007.

Moore NT, Senger DR: Vascular permeability factor: an important mediator of angiogenesis in vitro. J Cell Biol 147: 831-844, 1999.

van Nieuw Amerongen GP, Koolwijk P, Versteijl A and van Hinsberg VV: Involvement of RhoA/Rho kinase signaling in VEGF-induced endothelial cell migration and angiogenesis in vitro. Atheroscler Thromb Vasc Biol 23: 211-217, 2002.

Zhao L, Xu G, Zhou J, et al: The effect of RhoA on human umbilical vein endothelial cell migration and angiogenesis in vitro. Oncol Rep 15: 1147-1152, 2006.

Van Aelst L and D’Souza-Schorey C: Rho GTAPases and signaling networks. Genes Dev 11: 2295-2322, 1997.

Glotzer M: Animal cell cytokinesis. Annu Rev Cell Dev Biol 13: 565-592, 1997.